Files
Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/149576
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2-CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer
Subject
Subject (English)
Citation
Citation
BLASCO-BENITO, Sandra, et al. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2019. Vol. 116, num. 9, pags. 3863-3872. ISSN 0027-8424. [consulted: 12 of June of 2026]. Available at: https://hdl.handle.net/2445/149576